Indomethacin (Indocin) veterinary-grade API enters companion animal tablet production as the free acid, micronized to a D90 below 20 µm before wet granulation because the drug substance is practically insoluble in water and dissolution from a non-disintegrated core is pH-dependent. The formulation addition ratio is 10% w/w when a 25 mg strength is compressed onto a 250 mg core, and 12.5% w/w when a 50 mg strength is prepared on a 400 mg core; both loadings are selected to keep the tablet mass within the compression range of veterinary dispensing tools. The manufacturing sequence uses pregelatinized starch and povidone K30 as binders in a high-shear granulator operated at impeller speed 150–250 rpm and chopper speed 1,500–3,000 rpm, followed by wet mass screening through a 0.8 mm sieve and fluid-bed drying at inlet temperature 55–65 °C until loss on drying reaches 1.5%–2.5%. The dried granulate is milled, blended with croscarmellose sodium and magnesium stearate, and compressed on a rotary tablet press at main compression force 8–15 kN, yielding tablet hardness 60–90 N and friability below 0.5%. Compliance for this dosage form is governed by USP <905> uniformity of dosage units, USP <711> dissolution testing, and finished-product manufacture under 21 CFR Part 211, with elemental impurities assessed according to ICH Q3D. Terminal finished product types include uncoated tablets, scored tablets, and film-coated tablets in 25 mg and 50 mg strengths packaged in induction-sealed HDPE bottles with desiccant; these are intended for companion animal therapy where authorized by national veterinary drug authorities and are not assigned to food-producing species because no maximum residue limit has been established.

What limits terminal sterilization of aqueous indomethacin sodium injections?

Aqueous injectable preparations of indomethacin are produced from the sodium salt or by in situ neutralization of the free acid with sodium hydroxide in Water for Injection, because the free acid cannot achieve the 1 mg/mL and 5 mg/mL target strengths without salt formation. The active pharmaceutical ingredient concentration is therefore 0.1% w/v for the 1 mg/mL strength and 0.5% w/v for the 5 mg/mL strength, with sodium chloride added to adjust osmolality to 280–320 mOsmol/kg. Terminal steam sterilization at 121 °C for 15 min is generally avoided for aqueous indomethacin sodium solutions because hydrolytic degradation accelerates above 80 °C and published stability data for veterinary formulations at these concentrations are limited; the preferred manufacturing route is therefore aseptic filtration through a 0.22 µm PVDF membrane into depyrogenated amber glass vials under Grade A conditions. The solution is prepared by nitrogen purging of Water for Injection until dissolved oxygen is below 0.2 mg/L, pH adjustment to 6.5–7.5 with 0.1 M sodium hydroxide, and cold holding at 2–8 °C before sterile filtration. Compliance requirements include USP <1> injections, USP <788> particulate matter in injections, 21 CFR Part 211, and stability evaluation aligned with VICH GL3 where a new veterinary product is registered. Finished product types are single-dose ampoules at 1 mg/mL and multi-dose vials at 5 mg/mL containing benzyl alcohol 1.5% v/v where preservatives are permitted; these injectables are restricted to companion equine or companion animal use in jurisdictions where equines are excluded from the food chain and the prescribing veterinarian has documented the extralabel indication.

When a sterile powder for reconstitution is specified for hospital use, the formulation relies on lyophilization of an aqueous indomethacin sodium solution rather than direct filling of the free acid, because the free acid has insufficient solubility in the small fill volume and would produce slow reconstitution. Each 10 mL vial contains 1 mg indomethacin as active ingredient and 50 mg mannitol as bulking agent, corresponding to an API concentration of 0.1% w/v in the pre-lyophilization solution at a 1 mL fill per vial. The compounded bulk solution is sterile-filtered through a 0.22 µm membrane, filled into depyrogenated glass vials, frozen at shelf temperature -40 °C for 4 h, then primary-dried at -20 °C under vacuum of 0.1 mbar for 24 h and secondary-dried at 25 °C until residual moisture is below 1.0%. Vials are stoppered under dry nitrogen and sealed with flip-off caps. Compliance for this sterile powder is linked to USP <1> injections, USP <921> water determination by Karl Fischer titration, 21 CFR Part 211 sterile manufacturing, and elemental impurity risk assessment under ICH Q3D. The reconstituted solution is prepared with 1 mL Water for Injection to yield 1 mg/mL for intravenous or intramuscular use in veterinary hospitals. Published data for this specific veterinary lyophilized configuration is limited; the stated cycle parameters are typical pharmaceutical lyophilization ranges rather than a regulatory submission batch record, and content uniformity of the lyophilized cake must be verified across the beginning, middle, and end of the freeze-drying shelf because heat transfer heterogeneity in production-scale lyophilizers can produce inter-vial moisture variation.

Oral suspension vehicles for exotic and zoological species

Oral liquid preparations containing indomethacin are manufactured for veterinary hospital use when solid dosage forms cannot be safely administered to small companion mammals, birds, or zoological patients requiring dose titration by body weight. The API is suspended rather than dissolved in aqueous vehicles because indomethacin free acid has pH-dependent solubility and remains practically insoluble at physiological pH; the target strengths are 5 mg/mL (0.5% w/v) and 10 mg/mL (1.0% w/v), prepared from micronized active ingredient dispersed into a structured vehicle containing xanthan gum 0.3% w/v, glycerol 20% v/v, sorbitol 30% v/v, and sodium benzoate 0.1% w/v as preservative. The dispersion step uses a high-shear homogenizer at 10,000 rpm for 15 min, followed by pH adjustment to 4.5–5.0 with citric acid and final particle-size control through a colloid mill with gap setting 100 µm. Finished suspensions must maintain a D90 below 30 µm by laser diffraction according to USP <429> to limit sedimentation rate and ensure consistent withdrawal during syringe dispensing. Compliance for these non-sterile liquids includes USP <795> for compounded nonsterile preparations or 21 CFR Part 211 for registered products, USP <1231> for pharmaceutical water quality, and stability assessment under ICH Q1A where commercial distribution is intended. Finished product types include amber PET bottles with CRC caps, oral dosing syringes graduated in millilitres, and unit-dose suspension sachets; labeling must state that the product is not for food-producing animals and must instruct vigorous shaking before use because indomethacin suspensions can form a firm sediment when stored at 15–25 °C for more than 72 h.

Non-sterile granules and premixes for equine top-dress application are produced by stepwise dilution of a milled indomethacin formulation onto a microcrystalline cellulose or lactose monohydrate carrier; the carrier selection changes the surface adsorption capacity and the blend uniformity endpoint because the API has a tendency to segregate when a dry-mix route is used without a binder. The premix is formulated at 0.5% w/w to deliver a 1 mg/kg bodyweight dose, so a 500 kg equine patient receives 500 mg of indomethacin in a 100 g top-dress portion. Manufacturing uses a low-shear plough mixer or ribbon blender operated at 15–25 rpm, with geometric dilution of the API after pre-blending with hydrophobic colloidal silica at 0.2% w/w to reduce electrostatic agglomeration. A binder solution of hypromellose 1% w/v is sprayed into the mixed powder, the wet mass is extruded through a 0.6 mm screen, spheronized, and dried in a fluid-bed dryer at inlet temperature 50–60 °C until loss on drying is below 2.0%. Blend uniformity is considered acceptable when assay values across 10 sampling points are within 90%–110% of label claim with relative standard deviation below 5.0%. Compliance must account for VICH GL11 stability testing, VICH GL18 residual solvent control, and applicable national veterinary drug GMP; because no maximum residue limit has been established for indomethacin in food-producing species, equine premix applications are only allowable where horses are permanently excluded from the human food chain and the exclusion is documented in the animal’s identification record. Finished product types include single-dose sachets, bulk jars with measuring scoops, and granulate-filled oral syringes for direct administration in equine hospitals.

When capsule filling demands weight correction for low-dose animal therapy

Hard gelatin and HPMC capsules containing 5 mg, 10 mg, or 25 mg indomethacin are used in companion animal practice where tablet splitting is unreliable and individualized dosing is required for small bodyweights. Capsule filling requires tighter weight correction than tablet compression because the API is present at 5% w/w for the 5 mg strength in a size 4 capsule with 100 mg fill weight, 10% w/w for the 10 mg strength, and 25% w/w for the 25 mg strength; the diluent is pre-dried lactose monohydrate with moisture below 1.0%, and magnesium stearate is added at 0.5% w/w as lubricant after a 15 min V-blender mixing step at 20 rpm. The powder is filled on a dosator-type capsule machine with pin tamping, where dosator volume and tamping pin pressure are adjusted to hold fill weight variation below 3.0% relative standard deviation; pre-compression plug height is controlled to prevent segregation of micronized indomethacin from the lactose diluent during transfer. Compliance for this dosage form includes USP <795> for nonsterile compounding or 21 CFR Part 211 for registered veterinary capsules, USP <905> uniformity of dosage units, USP <1174> powder flow testing, and ICH Q3D elemental impurities. Published data for specific veterinary capsule formulations of indomethacin is limited; therefore capsule content uniformity should be verified across filling speed ranges and at the beginning, middle, and end of each production run rather than inferred from the tablet data alone. Finished product types are hard gelatin capsules in blister packaging or HDPE bottles with desiccant, with strengths selected according to the prescribing veterinarian’s dose calculation and dispensed only for non-food-producing companion animals.